AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01227707
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 825 mg/m2 twice daily orally, 38 days
Trial: NCT01227707
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
Trial: NCT02699710
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid will be administered orally as tablet at a single dose of 5 mg.
Trial: NCT02108223
Drug: fix dose r-FSH (Gonal-f)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle stimulation
Trial: NCT02108223
Drug: r-LH supplementation
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant luteinizing hormone
Trial: NCT02108223
Drug: r-FSH (Gonal-f)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle stimulation hormone
Trial: NCT02699710
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
Trial: NCT04314674
Drug: %3 HS bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After head fixation %3 HS bolus 3 ml/kg will be administered
Trial: NCT04314674
Drug: %3 HS infusion 20 ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After head fixation %3 HS 20 ml/h infusion will be administered
Trial: NCT00005581
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005581
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02989662
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 6 doses
Trial: NCT03103412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02817243
Drug: SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Trial: NCT02817243
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
Trial: NCT01855360
Drug: Tauroursodeoxycholic Acid and Doxycycline
RxNorm normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02709603
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo; 2 tablets 30 minutes before the procedure
Trial: NCT01060696
Drug: Mefenamic acid or Hyoscine or placebo
RxNorm normalized name: salicylic acid Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
Trial: NCT01966913
Drug: ICE chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
Trial: NCT02628704
Drug: Placebo (for selinexor)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar tablet manufactured to mimic selinexor tablet
Trial: NCT00209092
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
Trial: NCT00811057
Drug: 1 Magnesium Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
Trial: NCT00811057
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
Trial: NCT02607943
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
Trial: NCT00748423
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NO in inhalation for 3 days
Trial: NCT00748423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in inhalation for 3 days
Trial: NCT00549445
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg daily
Trial: NCT00549445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily
Trial: NCT01301833
Drug: alpha-glucosidase inhibitor
RxNorm normalized name: Alpha-glucosidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02774148
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
Trial: NCT02774148
Drug: PO Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 1,000mg po Acetaminophen every 8 hours.
Trial: NCT01813448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01612130
Drug: Placebo 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
Trial: NCT01709656
Drug: celecoxib, Celebrex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up
Trial: NCT02663622
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acute GVHD prophylaxis
Trial: NCT02663622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml saline IV infusion.
Trial: NCT02611232
Drug: Victoza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Trial: NCT02611232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Trial: NCT00392678
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
Trial: NCT00392678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Salsalate
Trial: NCT00380627
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02112292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02809118
Drug: AM-111 0.4 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
Trial: NCT02809118
Drug: AM-111 0.8 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
Trial: NCT00443625
Drug: SK3530
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844791
Drug: OCZ103-OS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCZ103-OS is given in combination with chemotherapy each cycle
Trial: NCT00509028
Drug: Conventional Asthma Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Trial: NCT00904111
Drug: Lidoderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Trial: NCT02055287
Drug: LY03004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00904111
Drug: Placebo Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Trial: NCT00114855
Drug: HYPOCOL®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03088527
Drug: RAD140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD140 will be supplied as formulated drug-in-capsules for oral administration.
Trial: NCT02008344
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily
Trial: NCT02493335
Drug: Placebo orodispersible tablet twice daily
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02255955
Drug: 550 mg naproxen sodium and 30mg codeine
RxNorm normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative contramal consumption, pain intensity, side effects
Trial: NCT02255955
Drug: 300 mg paracetamol and 30 mg codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative contramal consumption, pain intensity, side effects
Trial: NCT02255955
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative contramal consumption, pain intensity, side effects
Trial: NCT00798473
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
Trial: NCT00711412
Drug: Induction Therapy - Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
Trial: NCT00561288
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1000 mg doses per day
Trial: NCT00711412
Drug: Combination Therapy - Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
Trial: NCT04318444
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
Trial: NCT02005588
Drug: amino acid chelated iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
Trial: NCT02005588
Drug: iron salt (ferrous fumarate)
RxNorm normalized name: iron bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
Trial: NCT01043211
Drug: Lidocaine Hydrochoride Injection, without epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
Trial: NCT04699669
Drug: CBL-514, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.
Trial: NCT01043211
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
Trial: NCT01043211
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
Trial: NCT03201614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
Trial: NCT00371020
Drug: low molecular weight heparin, 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00441727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00844012
Drug: Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
Trial: NCT01702025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow corn meal in gel capsules
Trial: NCT03053401
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
Trial: NCT04741295
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
Trial: NCT00533169
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
Trial: NCT03802240
Drug: IBI305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg IV Q3W
Trial: NCT00704938
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/kg/day (Days-7,-6)
Trial: NCT03802240
Drug: Placebo1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo1 IV Q3W
Trial: NCT04572698
Drug: LY09004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
Trial: NCT03321890
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, 50mg / day,after lunch
Trial: NCT03321890
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, 10mg / times, once a week,after breakfast
Trial: NCT04002258
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
Trial: NCT00038103
Drug: Celecoxib + Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
Trial: NCT05482828
Drug: JGT (Jaeumgeonbi-Tang) tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
Trial: NCT05482828
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
Trial: NCT02784327
Drug: PRF110
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03132324
Drug: INCB059872
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB059872 tablets
Trial: NCT02200952
Drug: recombinant LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant LH twice/day for 10 days from pick up
Trial: NCT03234816
Drug: Norepinephrine 0.05 mcg /Kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Trial: NCT03234816
Drug: Norepinephrine 0.1 mcg /Kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Trial: NCT03234816
Drug: Norepinephrine 0.15 mcg /Kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Trial: NCT03254394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water will be administered as active comparator.
Trial: NCT03254394
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days.
Trial: NCT02473562
Drug: Placebo (for varenicline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet 1 mg BID
Trial: NCT02317016
Drug: AZD9291 tablet dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
Trial: NCT02317016
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
Trial: NCT01670110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be injected once per month
Trial: NCT00966199
Drug: anti-hypertensive medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
Trial: NCT02300259
Drug: LY2623091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02300259
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01285934
Drug: intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.